JAN JanOne

JanOne is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The company is also exploring solutions for non-addictive pain medications. Its lead candidate JAN101 is for treating peripheral artery disease ('PAD'), a condition that affects over 8.5 million Americans. JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase 2b trials are expected to begin in early 2021. JanOne is dedicated to funding resources toward innovation, technology, and education for PAD, associated vascular conditions and neuropathic pain.

Company profile

Tony Isaac
Fiscal year end
Former names
IRS number

JAN stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


17 May 21
4 Aug 21
2 Jan 22
Quarter (USD)
Apr 21 Jan 21 Sep 20 Jun 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Jan 21 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from JanOne earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 5.06M 5.06M 5.06M 5.06M 5.06M 5.06M
Cash burn (monthly) (positive/no burn) (positive/no burn) 703K 695K 114K 137.92K
Cash used (since last report) n/a n/a 2.84M 2.81M 460.74K 557.4K
Cash remaining n/a n/a 2.22M 2.25M 4.6M 4.5M
Runway (months of cash) n/a n/a 3.2 3.2 40.3 32.6

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
24 May 21 Virland A Johnson Common Shares Sell Dispose S No No 6.7 32,933 220.65K 0
5 Feb 21 Virland A Johnson Common Stock Sell Dispose S No No 8.65 4,112 35.57K 32,933
3 Nov 20 Virland A Johnson Common Stock Sell Dispose S No No 3.61 1,469 5.3K 37,045
31 Mar 20 Virland A Johnson Common Shares Sell Dispose S No No 2.19 4,900 10.73K 38,514
27 Mar 20 Virland A Johnson Common Shares Sell Dispose S No No 2.21 1,900 4.2K 43,414
25 Mar 20 Virland A Johnson Common Shares Sell Dispose S No No 2.19 6,686 14.64K 45,314

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

10.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 9 7 +28.6%
Opened positions 5 6 -16.7%
Closed positions 2 0 NEW
Increased positions 2 0 NEW
Reduced positions 1 0 NEW
13F shares
Current Prev Q Change
Total value 2.49M 45K +5428.9%
Total shares 282.24K 9.24K +2956.2%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Altium Capital Management 190.48K $1.72M NEW
Citadel Advisors 31.97K $269K NEW
Vanguard 23.8K $200K NEW
GS Goldman Sachs 20.81K $175K NEW
Renaissance Technologies 12.2K $103K NEW
UBS UBS Group AG - Registered Shares 2.7K $23K -49.6%
BLK Blackrock 173 $1K 0.0%
MS Morgan Stanley 100 $1K +9900.0%
WFC Wells Fargo & Co. 12 $0 +50.0%
Proequities 0 $0
Largest transactions
Shares Bought/sold Change
Altium Capital Management 190.48K +190.48K NEW
Citadel Advisors 31.97K +31.97K NEW
Vanguard 23.8K +23.8K NEW
GS Goldman Sachs 20.81K +20.81K NEW
Renaissance Technologies 12.2K +12.2K NEW
Tower Research Capital 0 -3.69K EXIT
UBS UBS Group AG - Registered Shares 2.7K -2.65K -49.6%
MS Morgan Stanley 100 +99 +9900.0%
WFC Wells Fargo & Co. 12 +4 +50.0%
BAC Bank Of America 0 -4 EXIT

Financial report summary

  • If we fail to implement our biopharmaceutical business strategy or if our biopharmaceutical business strategy is ineffective, our financial performance could be materially and adversely affected.
  • We have identified and disclosed in this Form 10-K material weaknesses in our internal control over financial reporting. If we are not able to remediate these material weaknesses and maintain an effective system of internal controls, we may not be able to accurately or timely report our financial results, which could cause our stock price to fall or result in our stock being delisted.
  • Our business model is entirely dependent on certain patent rights licensed to us from the Licensors (as defined below), and the loss of those license rights would, in all likelihood, cause our business, as presently contemplated, to fail.
  • Even if we receive regulatory approval for our product candidate, we may not be able to successfully commercialize the product and the revenue that we generate from its sales, if any, may be limited.
  • Even if we obtain marketing approval for our product candidate, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidate could be subject to labeling and other restrictions and withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidate.
  • Obtaining and maintaining regulatory approval of our product candidate in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidate in other jurisdictions.
  • Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.
  • Third-party coverage and reimbursement and health care cost containment initiatives and treatment guidelines may constrain our future revenues.
  • It is difficult and costly to protect our intellectual property rights, and we cannot ensure the protection of these rights.
  • It is difficult and costly to block others from developing similar products for other indications, and we cannot ensure that these products will not be less expensive and thus be prescribed off-label by physicians for use in our indications.
  • Our product candidate may infringe the intellectual property rights of others, which could increase our costs and delay or prevent our development and commercialization efforts.
  • Our revenues, earnings and cash flows will fluctuate based on changes in commodity prices.
  • We purchase our replacement appliances from third-party manufacturers, who we believe manufacture those appliances in China and Mexico, and, as a result, international trade conditions could adversely affect us.
  • If our third-party collection or delivery services are unable to meet our promised pickup and delivery schedules, our net sales may decline due to a decline in customer satisfaction.
  • Our sales may not be an indication of our future results of operations because they fluctuate significantly.
  • Significant shortages in diesel fuel supply or increases in diesel fuel prices will increase our operating expenses.
  • Our revenues from recycling contracts are subject to seasonal fluctuations and are dependent on the utilities’ advertising and promotional activities for contracts in which we do not provide advertising services.
  • GeoTraq has incurred significant operating losses since inception and expects the losses will continue into the future. If the losses continue GeoTraq may have to suspend operations or cease operations.
  • GeoTraq does not have sufficient funds to complete each phase of its proposed plan of operation and as a result may have to suspend operations.
  • GeoTraq outsources the research and development of its technology, and as a result it is dependent upon those third-party developers to develop our products in a timely and cost-efficient manner while maintaining a minimum level of quality.
  • Cellular service providers on which GeoTraq’s technology is dependent may change the terms by which the technology is used on their networks, which could result in lower revenue and adverse effects on our business.
  • GeoTraq’s ability to increase or maintain its customer base and revenue will be impaired if cellular service providers do not allow GeoTraq Technology access to their networks.
  • Isaac Capital Group, LLC (“ICG”) owns a large percentage of our voting stock, which may allow them to control substantially all matters requiring stockholder approval.
Management Discussion
  • Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
  • Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to provide a reader of our financial statements with a narrative from the perspective of our management on our financial condition, results of operations, liquidity and certain other factors that may affect our future results. Dollars stated in thousands, except per share amounts.
  • This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which involve risks and uncertainties. You can identify forward-looking statements because they contain words such as ‘‘believes,’’ ‘‘expects,’’ ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘seeks,’’ ‘‘approximately,’’ ‘‘intends,’’ ‘‘plans,’’ ‘‘estimates’’ or ‘‘anticipates’’ or similar expressions that concern our strategy, plans or intentions. Any statements we make relating to our future operations, performance and results, and anticipated liquidity are forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may change at any time, and, therefore, our actual results may differ materially from those we expected. We derive most of our forward-looking statements from our operating budgets and forecasts, which are based upon many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and, of course, it is impossible for us to anticipate all factors that could affect our actual results. Important factors that could cause actual results to differ materially from our expectations, including, without limitation, in conjunction with the forward-looking statements included in this Form 10-Q, are disclosed in “Item 1-Business, Item 1A – Risk Factors” of our Form 10-K. Some of the factors that we believe could affect our results include:
Content analysis
8th grade Avg
New words: accurate, acknowledge, advocacy, Affiliated, Agency, agent, ancillary, assignment, backlog, bear, beneficial, break, clinical, Committee, COSO, digital, Disposition, earnout, educational, epidemic, equivalent, estate, Extension, factual, field, Framework, hereto, ICG, indemnification, innovative, Instance, introduced, KLC, Label, LBS, lead, leading, leaving, Linkbase, marketplace, Master, opioid, owner, par, patient, placement, priority, purpose, ranging, recently, recruit, recruitment, referenced, reimbursement, relied, rely, remote, repaid, Schema, shelf, slightly, Sponsoring, study, supervision, task, Taxonomy, thereof, travel, Treadway, unanimously, unknown, unrecognized, variant, viewed, waiting, Waiver, XBRL
Removed: AAP, achievement, admission, advantage, allegedly, alleging, amortizing, arbitration, arbitrator, arising, assist, ASU, awarded, calculate, Chicago, claimed, comparable, consolidate, created, dba, designed, EEI, effort, escrow, exchanged, exercisable, exposure, flexibility, gas, GE, GEA, Haier, idled, indemnify, ineffective, interference, Kentucky, led, length, longevity, manage, mutual, obligated, offsetting, pending, prejudice, prepaid, preserve, proceeding, promulgated, prospective, PSP, Recleim, rendering, returned, SEC, Senior, serving, Simultaneously, sought, stayed, sublease, submit, subsequently, supplementary, temporarily, testing, venued, vest, Western